EpiWatch develops prescription software—an app that monitors smartwatch wearers for epileptic seizures and alerts caregivers. The app also logs post-seizure data to train an algorithm intended to predict future episodes. Its innovation is enabling seizure monitoring on mainstream devices like the Apple Watch rather than a separate medical wearable. The company spun out of Johns Hopkins University School of Medicine’s Technology Innovation Center, and is led by CEO Dean Papadopoulos. EpiWatch completed a $415,000 raise to fund a clinical study designed to provide FDA evidence that its software can track seizures and coordinate lifesaving care. Papadopoulos expects the study to conclude by year-end and for the app to reach market next year if the FDA approves it; the company notes the app would initially be available only through Apple Watches. The firm may require additional trials to implement on other smartwatch platforms depending on FDA requirements.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2022